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The parasitic disease human African trypanomiasis (HAT),
also known as sleeping sickness, is a highly neglected fatal
condition endemic in sub-Saharan Africa, which is poorly
treated with medicines that are toxic, no longer effective or
very difficult to administer. New, safe, effective and
easy-to-use treatments are urgently needed. Many nitro-
imidazoles possess antibacterial and antiprotozoal activity
and examples such as tinidazole are used to treat
trichomoniasis and guardiasis, but concerns about toxicity
including genotoxicity limit their usefulness. Fexinidazole,
a 2-substituted 5-nitroimidazole rediscovered by the Drugs
for Neglected Diseases initiative (DNDi) after extensive
compound mining of public and pharmaceutical company
databases, has the potential to become a short-course, safe
and effective oral treatment, curing both acute and chronic
HAT. This paper describes the genotoxicity profile of
fexinidazole and its two active metabolites, the sulfoxide
and sulfone derivatives. All the three compounds are
mutagenic in the Salmonella/Ames test; however, mutage-
nicity is either attenuated or lost in Ames Salmonella
strains that lack one or more nitroreductase(s). It is known
that these enzymes can nitroreduce compounds with low
redox potentials, whereas their mammalian cell counter-
parts cannot, under normal conditions. Fexinidazole and
its metabolites have low redox potentials and all mamma-
lian cell assays to detect genetic toxicity, conducted for this
study either in vitro (micronucleus test in human lympho-
cytes) or in vivo (ex vivo unscheduled DNA synthesis in
rats; bone marrow micronucleus test in mice), were
negative. Thus, fexinidazole does not pose a genotoxic
hazard to patients and represents a promising drug
candidate for HAT. Fexinidazole is expected to enter Phase
II clinical trials in 2012.
Introduction
An estimated 60 million people in sub-Saharan African
countries are at risk for human African trypanomiasis (HAT),
especially poor and neglected populations living in remote
areas (1,2). In west and central Africa where it is endemic,
Trypanosoma brucei gambiense causes a chronic form of
sleeping sickness, whereas in eastern and southern Africa, T. b.
rhodesiense causes an acute form of the disease. HAT occurs in
two stages: Stage 1 (early haemolymphatic) is characterised by
non-specific clinical symptoms, such as malaise, headache,
fever and peripheral oedema, whereas Stage 2 (late menin-
goencephalic) is characterised by neurological symptoms,
including behavioural changes, severe sleeping disturbances
and convulsions, which, if left untreated, lead to coma and
death in 100% of cases. There are few current treatments for
HAT and these are old, limited due to toxicity, diminishing in
efficacy and can be complex to use. Treatment is stage-specific,
and the only therapies available for Stage 2 are the more
difficult to administer or more toxic drugs (3,4). There is
a pressing need for new, safe and effective treatments for HAT,
preferably oral drugs that can treat both stages.
There are many nitroheterocyclic compounds, including
nitroimidazoles, which possess good oral therapeutic activity
against protozoal parasites; however, concerns over toxicity
and in particular genotoxicity has made drug development
problematical. A typical anti-trypanosomal nitroimidazole is
megazol (5) but its development was abandoned because of
genotoxicity in bacteria and in mammalian systems with the
resulting concerns about carcinogenicity (6). Another example
is metronidazole (7), which is widely used as an antibiotic and
antiprotozoal treatment. While the potential risks posed by the
genotoxicity and carcinogenicity of metronidazole are still
areas of active controversy (8), the therapeutic usefulness of
this compound, including the lack of evidence of clinical
toxicity, despite widespread use, has kept the drug in the
arsenal of key antimcicrobial drugs, included on the World
Health Organisation (WHO) list of Essential Medicines (9).
Tinidazole, which is closely related to metronidazole, is used
for the treatment of a variety of parasitic and bacterial
infections (10). Nifurtimox and benznidazole used for the
treatment of Chagas disease, also caused by a trypanosome
(11), are further members of the class. These compounds
possess both bacterial and mammalian cell genotoxicity (12,13)
and thus generate concern in terms of adverse long-term health
effects (14). However, when no safer alternative therapeutic
options are available, the medical benefit of treating patients
with these drugs is considered to outweigh their risks.
Compounds containing nitro groups are known to be
activated by various enzymes, including nitroreductases, to
form reactive radicals. This bioreduction requires low redox
electron transfer systems. In general, the single-electron
reduction potential of nitroimidazoles lies outside the normal
range of mammalian redox systems (15). However, if a one-
electron reduction of these compounds does occur, this can
lead to the formation of a hydroxylamine intermediate, an
unstable nitro radical anion that can go on to form a nitrite
anion and an imidazole radical or be further reduced by
accepting a second electron (16). In the presence of oxygen,
this can lead to the generation of a superoxide radical and then
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on to the formation of highly genotoxic nitroso derivatives
(17). Most of these reactive chemical species have the potential
to interact with DNA.
The bacterial mutagenicity of many members of this group
of compounds (often in both base-substitution strains such as
TA100 and in frameshift-detecting strains such as TA98) has
been known for many years (18). Nitroreduction is essential for
the expression of this mutagenicity, as shown for example in
tests of the anti-schistosomal drug niridazole, such that activity
is reduced 10-fold in nitroreductase-deficient TA100 and TA98
Salmonella strains compared to their nitroreductase-proficient
counterparts. In addition, the desnitro analogue is not
mutagenic (19). These results were confirmed by Speck et al.
(20) who extended the findings to show niridazole is also
mutagenic for TA102, which has an A–T mutational site in the
target of his G gene compared to the G–T sites in the target
genes for mutation in TA100 and TA98. Again, these authors
showed that mutagenicity is attenuated in a TA102 strain with
a nitroreductase deficiency.
In view of the notable oral anti-infective or anti-parasitic
activities observed in this class of compounds, there have been
many attempts to separate the anti-parasitic activity, of relevant
nitroheterocyclic compounds, from genotoxicity, with varying
degrees of success (21–24). The difficulty remains that the anti-
parasitic mode of action of these compounds is to produce
genotoxic compounds as a result of nitroreduction within the
parasite, with subsequent lethal effects on the parasite. In
a study on the resistance of trypanosomes to nifurtimox and
benznidazole, it was shown that both drugs are activated by an
nicotinamide adenine dinucleotide reduced-dependent, mito-
chondrially located, bacterial-like type 1 nitroreductase. Re-
sistance appears to be due to downregulation of this enzyme.
Loss of a single copy of this gene is sufficient to cause cross-
resistance to a wide variety of nitroheterocyclic compounds
(25,26).
Thus, bacteria and parasites including trypanosomes possess
low redox electron transfer systems capable of carrying out the
nitroreduction and generating toxic compounds. The promise
and the challenge were to find a compound that can be
efficiently nitroreduced by the target parasites but not by
equivalent mammalian enzymes.
Several new nitroimidazole drug candidates have emerged
recently, of which PA-824 (27) and OPC-67683 (28) are
currently in clinical development for the treatment of tuberculosis.
Published data have indicated that neither of these compounds
appears to possess genotoxicity, including in the Ames test,
showing that it is possible and feasible to synthesise
nitroimidazoles devoid of mutagenicity.
This paper describes a genotoxicity evaluation of fexinida-
zole (1H-imidazole,1-methyl-2-[[4-methylthio) phenoxy]
methyl] 5-nitroimidazole), a 2-substituted 5-nitroimidazole,
rediscovered by the Drugs for Neglected Diseases initiative
(DNDi) after extensive compound mining of drug companies
and published databases. It was first synthesised by Hoechst
and described in 1978 (29). It was shown to possess potent in
vitro and in vivo activity against trichomonads, Entamoeba
histolytica, Trypanosoma cruzi and Trypanosoma brucei
infections in mice (30). The principal metabolites, sulfoxide
and sulfone derivatives, were shown to have equivalent
anti-parasitic activity to the parent molecule (31). However,
the development of this drug candidate was not pursued by
Hoechst beyond preclinical studies. A detailed reassessment of
the pharmacological and toxicological profile of fexinidazole,
according to the current state of the art, has validated the
compound as a promising drug candidate for HAT (32), and
Phase I clinical studies are currently ongoing.
Materials and methods
All studies described in this paper were carried under good laboratory practice
(GLP) regulations, except where indicated.
Test compounds
Fexinidazole, 1H-imidazole,1-methyl-2-[[4-methylthio)phenoxy] methyl] 5-
nitroimidazole, was manufactured for DNDi by Centipharm Ltd, Grasse,
France, under current good manufacturing practice (cGMP) conditions and had
a purity of .99.0%. Fexinidazole sulfone, 1-methyl-2-(4-methylsulfonyl
phenoxymethyl)-5-nitroimidazole was manufactured by Centipharm Ltd and
had a nominal purity of 99.9%. The structures of these compounds are shown in
Figure 1.
Positive control compounds used were as follows:
Ames tests: 2-nitrofluorene (2NF), sodium azide, 4-nitroquinoline 1-oxide
(4NQO), metronidazole (MTZ), 9-aminoacridine (9-AC), mitomycin C (MMC),
benzo(a)pyrene (B(a)P), 2-aminoanthracene(2-AA) and nitrofurantoin (NFu).
In vitro micronucleus test: 4NQO, cyclophosphamide and vinblastine.
In vivo bone marrow micronucleus test in the mouse: cyclophosphamide.
Ex vivo unscheduled DNA synthesis (UDS) study in the rat: 2-acetamido-
fluorene and dimethylnitrosamine.
All positive control compounds were of high grade and obtained from
Sigma–Aldrich Chemical Company, Poole, Dorset, UK.
Drug preparation
Fexinidazole and the sulfone metabolite were prepared for in vitro studies as
stock solutions in dimethyl sulphoxide (DMSO), further diluted with water or
0.5% methylcellulose in water to appropriate concentration required for the
assays. For in vivo studies, fexinidazole was prepared as an optimised
suspension comprising 5% w/v Tween 80/0.5% w/v Methocel in water.
Test systems
Salmonella typhimurium strains TA98, TA100, TA1535 and TA1537 were
originally obtained from the UK NCTC. Strain TA102 was derived from
a culture obtained from GlaxoSmithKline Limited. Strain TA98NR was derived
from a culture obtained from the University of York Cancer Research Unit and
TA100NR was derived from a culture obtained from Novartis Pharma AG,
Switzerland. Strains TA1535NR, YG7167 YG7168 and YG7127 were
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TA98NR, TA100NR and TA1535NR are variants of strain TA98, TA100 and
TA1535, respectively, that are deficient in ‘classical’ nitroreductase activity.
Strain YG7127 is a further variant of strain TA1535 that has the classical
nitroreductase gene deleted. Similarly, strainsYG7167 and YG7168 are variants
of the strains TA1537 and TA102, respectively, with the classical nitro-
reductase gene deleted. These latter strains were specifically constructed for this
study by targeted disruption of the cnr gene (classical nitroreductase) using
techniques published previously (33).
Young adult male Crl:CD-1 (ICR) mice were used for the bone marrow
micronucleus test and young male Sprague–Dawley rats for the ex vivo liver
UDS test.
Bacterial mutation assays (Ames test)
When the Salmonella typhimurium TA strains were first constructed by Bruce
Ames and colleagues, uvrB mutants were selected, removing the main DNA
excision repair pathway, by scoring cultures for chlorate resistance. The gene
conferring chlorate resistance is in close proximity to the uvrB gene; thus, those
cells acquiring chlorate resistance as a result of a deletion were likely to also have
lost the uvrB gene as well. As each strain was selected independently, the
commonly used Salmonella strains used in the Ames test have differently sized
deletions. Thus, 47 genes are missing in TA100, 87 in TA1537 and 119 in TA98.
Importantly, for this work, a major supplementary nitroreductase is absent in
TA98 (and also in TA1535) as a result of these deletions (34). Thus, for TA98NR
and TA1535NR, these strains lack the two important nitroreductases for
Salmonella, while the other NR strains used only lack the classical nitroreductase.
To evaluate bacterial mutagenicity, full Ames tests were carried out on
fexinidazole and fexinidazole sulfone using the five strains of Salmonella
typhimurium recommended by the relevant International Conference for
Harmonisation (ICH) regulatory guideline, as well as the corresponding
nitroreductase-deficient strains, as above. Standard bacterial plate incorporation
assays were carried out, essentially as described by Maron and Ames (35).
Tests on fexinidazole were carried out with and without rat liver post-
mitochondrial fraction plus co-factors (S9 mix) to provide a mammalian
metabolic activation system. The S9 fraction was prepared from Sprague–
Dawley rats pretreated with the mixed cytochrome P 450 enzyme inducer
Aroclor 1254. A total of 0.5 ml of S9 mix containing 10% S9 fraction was
added to 2.5 ml agar overlays.
Tests on fexinidazole sulfone were carried out only in the absence of rat
liver S9 (as this is a metabolite). After incubation at 37C for 3 days, plates
were scored for mutant colonies using a Seescan Colony Counter (Seescan plc).
In vitro micronucleus tests using human lymphocytes
Duplicate human lymphocyte cultures were prepared from the pooled blood of
two donors in two independent experiments as defined in the OECD Guideline
487 (36). For fexinidazole, treatments covering a broad range of concentrations,
separated by narrow intervals, were carried both in the absence and in the
presence of metabolic activation rat liver (S9). The final concentration of S9
fraction in the media used for this test was 2%.
The highest concentration of fexinidazole tested was 220 lg/ml. Cells were
treated with the drug 24 and 48 h following stimulation by the mitogen
phytohaemagglutinin (PHA). In the absence of S9, the exposure period was 20 h
plus a 28-h expression period (�S9) or for 3 h with a 45-h expression period
(þS9). The test concentrations for analyses of micronuclei were selected by
evaluating the effect of fexinidazole on the replication index. In each experiment,
micronuclei were analysed at three concentrations. The highest concentrations
tested were limited by precipitation observed at the end of the treatment period.
Similar tests were carried out on fexinidazole sulfone. As per the Ames test,
this was carried out in the absence of rat liver S9 only. In this case, the cells
were treated 48 h after mitogen stimulation with PHA and as there were no tests
in the presence of S9, an extended exposure period was included (24 h, no
expression time).
Mouse bone marrow micronucleus test
Groups of six Crl:CD-1 (ICR) male mice were treated with fexinidazole using
two oral doses of 0 (vehicle control), 500, 1000 or 2000 mg/kg given 24 h
apart, and bone marrows were harvested 24 h after the second dose (37). Slides
of bone marrow cells were prepared, Giemsa stained and 2000 polychromatic
erythrocytes per animal were scored for micronuclei. The percentage of
polychromatic erythrocytes of the total of erythrocytes in each bone marrow
sample was used to estimate toxicity.
Ex vivo UDS test in rat liver
The standard autoradiographic method was used (38). Groups four male
Sprague–Dawley Crl:CDd (SD) rats received fexinidazole doses of 500, 1000
or 2000 mg/kg orally (two groups per dose), and the livers were sampled either
2–4 h or 12–14 h after test compound administration. Hepatocyte suspensions
were prepared and incubated in the presence of tritiated thymidine. Slides of fixed
hepatocytes were coated in photographic emulsion and stored for 14 days at 4C
in the dark. The silver grains that accumulated in the emulsion due to radioactive
decay of the tritium were counted above both the nuclei and equivalent areas of
cytoplasm. Grain counting was performed using a microscope with a video
camera connected to an image analysis system (Perceptive Instruments) and
a computer programmed for automatic data capture. A total of 100 cells were
analysed per animal (50 from each of two slides). The extent of DNA repair was
estimated by calculating the mean of the difference between the nuclear and
cytoplasmic counts (nuclear net grain count) per sample.
All genotoxicology studies in animals were carried out by Covance
Laboratories Ltd, Harrogate, England, according to their internal Standard
Operating Procedures, the applicable ICH guidelines (ICH S2A,B) and in
compliance with the UK GLP Regulations 1999, Statutory Instrument No. 3106
as amended by the GLP (Codification Amendments Etc.) Regulations 2004 and
the OECD Principles on GLP (January 1998) ENV/MC/CHEM (98) 17. Animals
were maintained as required by the ‘Code of practice for the housing and care of
animals used in scientific procedures’ (Home Office, London, 1989).
Toxicokinetic measurements
Blood samples were taken from satellite animals from the bone marrow
micronucleus study and from the UDS study, 1 h after dosing with 2000 mg/kg
in each case. This is close to the Tmax for fexinidazole. Concentrations of
fexinidazole and its two major metabolites were determined in plasma from
these samples by a liquid chromatography-mass spectroscopy-mass-spectros-
copy (LC–MS–MS) method following plasma protein precipitation in a 96-well
plate format.
These analyses were carried out by The Bioanalysis and Analytical Control
Department, Neviano Medical Sciences, Accelera, Milan Italy. A preliminary
study using the same methodology had also been carried out at CIT, Evreux,
France, but in this study, samples were taken 4 h after dosing.
Metabolism of fexinidazole using Aroclor 1254-induced rat liver S9 fraction
Fexinidazole was incubated at a single nominal concentration of 200 lg/ml with
Aroclor 1254-induced rat liver S9 (1 mg/ml) at 37C for 0, 15 and 60 min.
Additional incubations were conducted with fexinidazole at a nominal
concentration of 200 lg/ml for 0, 2, 3 and 6 h. Aroclor 1254-induced rat liver
S9 and [14C]fexinidazole in Tris–HCl buffer, pH 7.4, were warmed to �37C for
�5 min before initiation of the reaction by the addition of nicotinamide adenine
dinucleotide phosphate reduced (2 mM). The total incubation volume was 0.2 ml.
All reactions were terminated by the addition of 0.1 ml acetonitrile. Incubations
were also conducted in the absence of rat liver S9. All test incubations were
conducted in triplicate. Following centrifugation (15 300g, 5 min), protein-free
supernatants were transferred to clean vials and stored frozen prior to analysis or
injected directly onto the high performance liquid chromatography system.
Recovery of radioactivity from each incubation mixture was measured by liquid
scintillation counting. Chromatographic data were captured online using
a validated data acquisition system (Laura 3.4.7; LabLogic Systems Ltd). All
other calculations were carried out using Excel 2003.
Nitroreductase measurements of selected Ames strains
Two new nitroreductase-deficient strains, TA1537NR (YG7167) and
TA102NR (YG7168), were kindly constructed for this project by Dr Y.
Yamada from the National Institute of Health Sciences Tokyo by disrupting the
gene for the supplementary nitroreductase, nsfB, using a procedure reported
previously (33). To confirm that the procedure had been successful,
nitroreductase measurements were made of extracts from these strains, their
nitroreductase parental strains and also the strain TA98NR. The procedure used
to quantify nitroreductase enzymatic activity was carried out at the University
of Swansea under contract and were not carried out under GLP conditions. The
nitroreductase activities of cell-free extracts from the selected strains were
estimated by the decrease in absorbance at 373 nm resulting from the reduction
of the nitrofurantoin substrate (39). Each strain was tested in parallel and the
whole procedure repeated on different days up to five times.
Redox potential measurement
One-electron reduction potentials were determined by fast kinetic spectropho-
tometry (pulse radiolysis) in aqueous solutions using an established procedure
(non-GLP) (40).
Results
Nitroreductase activities of selected strains
The nitroreductase activities of TA102/TA102NR (YG7168),
TA1537/TA1537NR (YG7167) and TA98NR are shown in
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on to the formation of highly genotoxic nitroso derivatives
(17). Most of these reactive chemical species have the potential
to interact with DNA.
The bacterial mutagenicity of many members of this group
of compounds (often in both base-substitution strains such as
TA100 and in frameshift-detecting strains such as TA98) has
been known for many years (18). Nitroreduction is essential for
the expression of this mutagenicity, as shown for example in
tests of the anti-schistosomal drug niridazole, such that activity
is reduced 10-fold in nitroreductase-deficient TA100 and TA98
Salmonella strains compared to their nitroreductase-proficient
counterparts. In addition, the desnitro analogue is not
mutagenic (19). These results were confirmed by Speck et al.
(20) who extended the findings to show niridazole is also
mutagenic for TA102, which has an A–T mutational site in the
target of his G gene compared to the G–T sites in the target
genes for mutation in TA100 and TA98. Again, these authors
showed that mutagenicity is attenuated in a TA102 strain with
a nitroreductase deficiency.
In view of the notable oral anti-infective or anti-parasitic
activities observed in this class of compounds, there have been
many attempts to separate the anti-parasitic activity, of relevant
nitroheterocyclic compounds, from genotoxicity, with varying
degrees of success (21–24). The difficulty remains that the anti-
parasitic mode of action of these compounds is to produce
genotoxic compounds as a result of nitroreduction within the
parasite, with subsequent lethal effects on the parasite. In
a study on the resistance of trypanosomes to nifurtimox and
benznidazole, it was shown that both drugs are activated by an
nicotinamide adenine dinucleotide reduced-dependent, mito-
chondrially located, bacterial-like type 1 nitroreductase. Re-
sistance appears to be due to downregulation of this enzyme.
Loss of a single copy of this gene is sufficient to cause cross-
resistance to a wide variety of nitroheterocyclic compounds
(25,26).
Thus, bacteria and parasites including trypanosomes possess
low redox electron transfer systems capable of carrying out the
nitroreduction and generating toxic compounds. The promise
and the challenge were to find a compound that can be
efficiently nitroreduced by the target parasites but not by
equivalent mammalian enzymes.
Several new nitroimidazole drug candidates have emerged
recently, of which PA-824 (27) and OPC-67683 (28) are
currently in clinical development for the treatment of tuberculosis.
Published data have indicated that neither of these compounds
appears to possess genotoxicity, including in the Ames test,
showing that it is possible and feasible to synthesise
nitroimidazoles devoid of mutagenicity.
This paper describes a genotoxicity evaluation of fexinida-
zole (1H-imidazole,1-methyl-2-[[4-methylthio) phenoxy]
methyl] 5-nitroimidazole), a 2-substituted 5-nitroimidazole,
rediscovered by the Drugs for Neglected Diseases initiative
(DNDi) after extensive compound mining of drug companies
and published databases. It was first synthesised by Hoechst
and described in 1978 (29). It was shown to possess potent in
vitro and in vivo activity against trichomonads, Entamoeba
histolytica, Trypanosoma cruzi and Trypanosoma brucei
infections in mice (30). The principal metabolites, sulfoxide
and sulfone derivatives, were shown to have equivalent
anti-parasitic activity to the parent molecule (31). However,
the development of this drug candidate was not pursued by
Hoechst beyond preclinical studies. A detailed reassessment of
the pharmacological and toxicological profile of fexinidazole,
according to the current state of the art, has validated the
compound as a promising drug candidate for HAT (32), and
Phase I clinical studies are currently ongoing.
Materials and methods
All studies described in this paper were carried under good laboratory practice
(GLP) regulations, except where indicated.
Test compounds
Fexinidazole, 1H-imidazole,1-methyl-2-[[4-methylthio)phenoxy] methyl] 5-
nitroimidazole, was manufactured for DNDi by Centipharm Ltd, Grasse,
France, under current good manufacturing practice (cGMP) conditions and had
a purity of .99.0%. Fexinidazole sulfone, 1-methyl-2-(4-methylsulfonyl
phenoxymethyl)-5-nitroimidazole was manufactured by Centipharm Ltd and
had a nominal purity of 99.9%. The structures of these compounds are shown in
Figure 1.
Positive control compounds used were as follows:
Ames tests: 2-nitrofluorene (2NF), sodium azide, 4-nitroquinoline 1-oxide
(4NQO), metronidazole (MTZ), 9-aminoacridine (9-AC), mitomycin C (MMC),
benzo(a)pyrene (B(a)P), 2-aminoanthracene(2-AA) and nitrofurantoin (NFu).
In vitro micronucleus test: 4NQO, cyclophosphamide and vinblastine.
In vivo bone marrow micronucleus test in the mouse: cyclophosphamide.
Ex vivo unscheduled DNA synthesis (UDS) study in the rat: 2-acetamido-
fluorene and dimethylnitrosamine.
All positive control compounds were of high grade and obtained from
Sigma–Aldrich Chemical Company, Poole, Dorset, UK.
Drug preparation
Fexinidazole and the sulfone metabolite were prepared for in vitro studies as
stock solutions in dimethyl sulphoxide (DMSO), further diluted with water or
0.5% methylcellulose in water to appropriate concentration required for the
assays. For in vivo studies, fexinidazole was prepared as an optimised
suspension comprising 5% w/v Tween 80/0.5% w/v Methocel in water.
Test systems
Salmonella typhimurium strains TA98, TA100, TA1535 and TA1537 were
originally obtained from the UK NCTC. Strain TA102 was derived from
a culture obtained from GlaxoSmithKline Limited. Strain TA98NR was derived
from a culture obtained from the University of York Cancer Research Unit and
TA100NR was derived from a culture obtained from Novartis Pharma AG,
Switzerland. Strains TA1535NR, YG7167 YG7168 and YG7127 were
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TA98NR, TA100NR and TA1535NR are variants of strain TA98, TA100 and
TA1535, respectively, that are deficient in ‘classical’ nitroreductase activity.
Strain YG7127 is a further variant of strain TA1535 that has the classical
nitroreductase gene deleted. Similarly, strainsYG7167 and YG7168 are variants
of the strains TA1537 and TA102, respectively, with the classical nitro-
reductase gene deleted. These latter strains were specifically constructed for this
study by targeted disruption of the cnr gene (classical nitroreductase) using
techniques published previously (33).
Young adult male Crl:CD-1 (ICR) mice were used for the bone marrow
micronucleus test and young male Sprague–Dawley rats for the ex vivo liver
UDS test.
Bacterial mutation assays (Ames test)
When the Salmonella typhimurium TA strains were first constructed by Bruce
Ames and colleagues, uvrB mutants were selected, removing the main DNA
excision repair pathway, by scoring cultures for chlorate resistance. The gene
conferring chlorate resistance is in close proximity to the uvrB gene; thus, those
cells acquiring chlorate resistance as a result of a deletion were likely to also have
lost the uvrB gene as well. As each strain was selected independently, the
commonly used Salmonella strains used in the Ames test have differently sized
deletions. Thus, 47 genes are missing in TA100, 87 in TA1537 and 119 in TA98.
Importantly, for this work, a major supplementary nitroreductase is absent in
TA98 (and also in TA1535) as a result of these deletions (34). Thus, for TA98NR
and TA1535NR, these strains lack the two important nitroreductases for
Salmonella, while the other NR strains used only lack the classical nitroreductase.
To evaluate bacterial mutagenicity, full Ames tests were carried out on
fexinidazole and fexinidazole sulfone using the five strains of Salmonella
typhimurium recommended by the relevant International Conference for
Harmonisation (ICH) regulatory guideline, as well as the corresponding
nitroreductase-deficient strains, as above. Standard bacterial plate incorporation
assays were carried out, essentially as described by Maron and Ames (35).
Tests on fexinidazole were carried out with and without rat liver post-
mitochondrial fraction plus co-factors (S9 mix) to provide a mammalian
metabolic activation system. The S9 fraction was prepared from Sprague–
Dawley rats pretreated with the mixed cytochrome P 450 enzyme inducer
Aroclor 1254. A total of 0.5 ml of S9 mix containing 10% S9 fraction was
added to 2.5 ml agar overlays.
Tests on fexinidazole sulfone were carried out only in the absence of rat
liver S9 (as this is a metabolite). After incubation at 37C for 3 days, plates
were scored for mutant colonies using a Seescan Colony Counter (Seescan plc).
In vitro micronucleus tests using human lymphocytes
Duplicate human lymphocyte cultures were prepared from the pooled blood of
two donors in two independent experiments as defined in the OECD Guideline
487 (36). For fexinidazole, treatments covering a broad range of concentrations,
separated by narrow intervals, were carried both in the absence and in the
presence of metabolic activation rat liver (S9). The final concentration of S9
fraction in the media used for this test was 2%.
The highest concentration of fexinidazole tested was 220 lg/ml. Cells were
treated with the drug 24 and 48 h following stimulation by the mitogen
phytohaemagglutinin (PHA). In the absence of S9, the exposure period was 20 h
plus a 28-h expression period (�S9) or for 3 h with a 45-h expression period
(þS9). The test concentrations for analyses of micronuclei were selected by
evaluating the effect of fexinidazole on the replication index. In each experiment,
micronuclei were analysed at three concentrations. The highest concentrations
tested were limited by precipitation observed at the end of the treatment period.
Similar tests were carried out on fexinidazole sulfone. As per the Ames test,
this was carried out in the absence of rat liver S9 only. In this case, the cells
were treated 48 h after mitogen stimulation with PHA and as there were no tests
in the presence of S9, an extended exposure period was included (24 h, no
expression time).
Mouse bone marrow micronucleus test
Groups of six Crl:CD-1 (ICR) male mice were treated with fexinidazole using
two oral doses of 0 (vehicle control), 500, 1000 or 2000 mg/kg given 24 h
apart, and bone marrows were harvested 24 h after the second dose (37). Slides
of bone marrow cells were prepared, Giemsa stained and 2000 polychromatic
erythrocytes per animal were scored for micronuclei. The percentage of
polychromatic erythrocytes of the total of erythrocytes in each bone marrow
sample was used to estimate toxicity.
Ex vivo UDS test in rat liver
The standard autoradiographic method was used (38). Groups four male
Sprague–Dawley Crl:CDd (SD) rats received fexinidazole doses of 500, 1000
or 2000 mg/kg orally (two groups per dose), and the livers were sampled either
2–4 h or 12–14 h after test compound administration. Hepatocyte suspensions
were prepared and incubated in the presence of tritiated thymidine. Slides of fixed
hepatocytes were coated in photographic emulsion and stored for 14 days at 4C
in the dark. The silver grains that accumulated in the emulsion due to radioactive
decay of the tritium were counted above both the nuclei and equivalent areas of
cytoplasm. Grain counting was performed using a microscope with a video
camera connected to an image analysis system (Perceptive Instruments) and
a computer programmed for automatic data capture. A total of 100 cells were
analysed per animal (50 from each of two slides). The extent of DNA repair was
estimated by calculating the mean of the difference between the nuclear and
cytoplasmic counts (nuclear net grain count) per sample.
All genotoxicology studies in animals were carried out by Covance
Laboratories Ltd, Harrogate, England, according to their internal Standard
Operating Procedures, the applicable ICH guidelines (ICH S2A,B) and in
compliance with the UK GLP Regulations 1999, Statutory Instrument No. 3106
as amended by the GLP (Codification Amendments Etc.) Regulations 2004 and
the OECD Principles on GLP (January 1998) ENV/MC/CHEM (98) 17. Animals
were maintained as required by the ‘Code of practice for the housing and care of
animals used in scientific procedures’ (Home Office, London, 1989).
Toxicokinetic measurements
Blood samples were taken from satellite animals from the bone marrow
micronucleus study and from the UDS study, 1 h after dosing with 2000 mg/kg
in each case. This is close to the Tmax for fexinidazole. Concentrations of
fexinidazole and its two major metabolites were determined in plasma from
these samples by a liquid chromatography-mass spectroscopy-mass-spectros-
copy (LC–MS–MS) method following plasma protein precipitation in a 96-well
plate format.
These analyses were carried out by The Bioanalysis and Analytical Control
Department, Neviano Medical Sciences, Accelera, Milan Italy. A preliminary
study using the same methodology had also been carried out at CIT, Evreux,
France, but in this study, samples were taken 4 h after dosing.
Metabolism of fexinidazole using Aroclor 1254-induced rat liver S9 fraction
Fexinidazole was incubated at a single nominal concentration of 200 lg/ml with
Aroclor 1254-induced rat liver S9 (1 mg/ml) at 37C for 0, 15 and 60 min.
Additional incubations were conducted with fexinidazole at a nominal
concentration of 200 lg/ml for 0, 2, 3 and 6 h. Aroclor 1254-induced rat liver
S9 and [14C]fexinidazole in Tris–HCl buffer, pH 7.4, were warmed to �37C for
�5 min before initiation of the reaction by the addition of nicotinamide adenine
dinucleotide phosphate reduced (2 mM). The total incubation volume was 0.2 ml.
All reactions were terminated by the addition of 0.1 ml acetonitrile. Incubations
were also conducted in the absence of rat liver S9. All test incubations were
conducted in triplicate. Following centrifugation (15 300g, 5 min), protein-free
supernatants were transferred to clean vials and stored frozen prior to analysis or
injected directly onto the high performance liquid chromatography system.
Recovery of radioactivity from each incubation mixture was measured by liquid
scintillation counting. Chromatographic data were captured online using
a validated data acquisition system (Laura 3.4.7; LabLogic Systems Ltd). All
other calculations were carried out using Excel 2003.
Nitroreductase measurements of selected Ames strains
Two new nitroreductase-deficient strains, TA1537NR (YG7167) and
TA102NR (YG7168), were kindly constructed for this project by Dr Y.
Yamada from the National Institute of Health Sciences Tokyo by disrupting the
gene for the supplementary nitroreductase, nsfB, using a procedure reported
previously (33). To confirm that the procedure had been successful,
nitroreductase measurements were made of extracts from these strains, their
nitroreductase parental strains and also the strain TA98NR. The procedure used
to quantify nitroreductase enzymatic activity was carried out at the University
of Swansea under contract and were not carried out under GLP conditions. The
nitroreductase activities of cell-free extracts from the selected strains were
estimated by the decrease in absorbance at 373 nm resulting from the reduction
of the nitrofurantoin substrate (39). Each strain was tested in parallel and the
whole procedure repeated on different days up to five times.
Redox potential measurement
One-electron reduction potentials were determined by fast kinetic spectropho-
tometry (pulse radiolysis) in aqueous solutions using an established procedure
(non-GLP) (40).
Results
Nitroreductase activities of selected strains
The nitroreductase activities of TA102/TA102NR (YG7168),
TA1537/TA1537NR (YG7167) and TA98NR are shown in
i it fi
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Figure 2. The data support the selection of the new NR strains
through the disruption of the nsfB gene as being truly
nitroreductase deficient. The remaining nitroreductase activity
seen in TA1537NR and TA102NR is presumably due at least
in part to the activity of the ‘classical nitroreductase gene
(cnr)’. It was surprising to see low levels of nitroreductase
activity remaining in TA98NR, which has lost the activity of
both nsfB and cnr genes, which suggests that there is a third
nitroreductase gene active in these cells. Although TA100 is
not included in these assay of nitroreductase activity, it is
known that it retains at least one functional nitroreductase (34)
and as shown in its sister strains.
In vitro metabolism of fexinidazole
In vivo studies had shown that fexinidazole is rapidly
metabolised to form the sulfoxide and the sulfone (see Table
VII from the toxicokinetic studies carried out to support the in
vivo genotoxicity tests); thus, the exposure is mainly to these
two metabolites. To ascertain that these two metabolites are
formed under the conditions of the in vitro genotoxicity
studies, in vitro metabolism was studied using rat liver S9. The
results show that the sulfoxide is formed rapidly and efficiently
under these conditions, but only trace amounts of the sulfone
are found (Figure 3). Therefore, the sulfone was synthesised
and tested separately, in addition to the parent molecule.
Ames tests of fexinidazole
Fexinidazole was tested in the five standard Salmonella strains
as required by the ICH guideline for genotoxicity testing for
pharmaceutical registration. In addition, to determine the
contribution of bacterial nitroreductase enzymes to mutagenic-
ity, the compound was also tested in the corresponding strains
deficient in one or two nitroreductases. A summary of the
results is shown in Table I. Figures 4–7 show the results for
TA98 and TA100 plus their nitroreductase-deficient counter-
parts, with (Figures 4 and 5) and without (Figures 6 and 7–9)
metabolic activation (S9). Mutagenicity was observed in all
strains to different degrees, except in TA1537 where the
original weak positive response was not reproducible. In each



































Fig. 3. Metabolism of fexinidazole in vitro following incubation with rat liver
S9 (HPLC data). Regions 1 and 2 represent the positions of fexinidazole
sulfone and fexinidazole sulfoxide, respectively.
Fig. 2. Nitroreductase activities of various strains used in this study, including
TA1537NR (YG7167) and TA102NR (YG7168).
Table I. Summary of Ames test data on fexinidazole showing the lowest
detectable mutagenic response (micrograms per plate)a
Ames strainb �S9 þS9
TA1535 20 4
TA1535NR Negative 350
TA1535 delta NR (YG7127) 350 4–20
TA1537 Negative 100 (negative
in a repeat study)






TA102NR (YG7168) Negative 158
aBased on a .2-fold increase in concurrent negative control values.
bStrains possessing active major nitroreductase (NR) genes—TA100, TA1537
and TA102 ; strains lacking an active classical NR gene—TA100NR; YG7127
(TA1535 derivative), YG7167 (TA1537 derivative) and YG7168 (TA102
derivative); strain lacking an active supplementary NR gene (TA98) and strains
lacking both major NR genes—TA98NR and TA1535NR.




or significantly attenuated (e.g. TA100NR versus TA100) in
the strains deficient in nitroreductase compared to their
nitoreductase-proficient counterpart. In the strains lacking both
the classical nitroreductase and the supplementary nitro-
reductase, i.e.TA98NR and TA1535NR, mutagenicity was all
but abolished, suggesting that the residual mutagenicity seen in
the other strains was due to the activity of the supplementary
nitroreductase. These data suggest that the positive mutage-
nicity signal observed for fexinidazole in the Ames test is due
to a reduction of fexinidazole by either or both bacterial
nitroreductases.
In most cases where mutagenicity was observed, potency of
the signal was increased in the presence of rat liver S9. As
fexinidazole is rapidly metabolised to its sulfoxide by rat liver
S9 (Figure 2), this suggests that this metabolite is a more active
bacterial mutagen than fexinidazole itself. In the absence of rat
liver S9, no activity was observed in TA102. However, activity
was observed in this strain in the presence of S9. These data
suggest that the sulfoxide possesses additional mutagenic
activity for this strain. However, again, activity was attenuated
in the nitroreductase-deficient derivative showing that nitro-
reduction plays a part in the mutagenicity observed.
Ames tests of fexinidazole sulfone
As only trace amounts of fexinidazole sulfone are formed by
incubation of fexinidazole with rat liver S9, this metabolite was
tested in its own right. As this compound is a metabolite, tests
were carried out in the absence of rat liver S9 only. The results
shown in Table II and Figures 8 and 9 for TA98 and TA100 (plus
their nitroreductase-deficient counterparts) demonstrate a broadly
similar result to fexinidazole, with mutagenic activity lost or
attenuated in the strains deficient in nitroreductase activity.
In vitro micronucleus tests of fexinidazole and fexinidazole
sulfone
Both fexinidazole and fexinidazole sulfone were subsequently
tested in in vitro micronucleus tests using human peripheral
lymphocytes. As it was shown that fexinidazole is metabolised
to its sulfoxide under the conditions of the assay, the results
shown in Table IIIa and b cover fexinidazole and fexinidazole
sulfoxide. The results for fexinidazole sulfone are shown in
Table IV. Neither compound induces chromosome damage in
human lymphocytes under the conditions of these assays. Thus,
the mutagenic potential seen in the bacterial Ames test is not
realised in these mammalian cells in vitro.
Fig. 6. Ames tests of fexinidazole using strains TA100 and TA100NR
(absence of S9).
Fig. 5. Ames tests of fexinidazole using strains TA98 and TA98NR (presence
of S9).
Fig. 7. Ames tests of fexinidazole using strains TA100 and TA100NR
(presence of S9).
Table II. Summary of Ames test data on fexinidazole sulfone showing the












aBased on a .2-fold increase in concurrent negative control values.
bStrains possessing active major nitroreductase (NR) genes—TA100, TA1537
and TA102; strains lacking an active classical NR gene—TA100NR; YG7167
(TA1537 derivative) and YG7168 (TA102 derivative); strain lacking an active
supplementary NR gene (TA98) and strains lacking both major NR
genes—TA98NR and TA1535NR.
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Figure 2. The data support the selection of the new NR strains
through the disruption of the nsfB gene as being truly
nitroreductase deficient. The remaining nitroreductase activity
seen in TA1537NR and TA102NR is presumably due at least
in part to the activity of the ‘classical nitroreductase gene
(cnr)’. It was surprising to see low levels of nitroreductase
activity remaining in TA98NR, which has lost the activity of
both nsfB and cnr genes, which suggests that there is a third
nitroreductase gene active in these cells. Although TA100 is
not included in these assay of nitroreductase activity, it is
known that it retains at least one functional nitroreductase (34)
and as shown in its sister strains.
In vitro metabolism of fexinidazole
In vivo studies had shown that fexinidazole is rapidly
metabolised to form the sulfoxide and the sulfone (see Table
VII from the toxicokinetic studies carried out to support the in
vivo genotoxicity tests); thus, the exposure is mainly to these
two metabolites. To ascertain that these two metabolites are
formed under the conditions of the in vitro genotoxicity
studies, in vitro metabolism was studied using rat liver S9. The
results show that the sulfoxide is formed rapidly and efficiently
under these conditions, but only trace amounts of the sulfone
are found (Figure 3). Therefore, the sulfone was synthesised
and tested separately, in addition to the parent molecule.
Ames tests of fexinidazole
Fexinidazole was tested in the five standard Salmonella strains
as required by the ICH guideline for genotoxicity testing for
pharmaceutical registration. In addition, to determine the
contribution of bacterial nitroreductase enzymes to mutagenic-
ity, the compound was also tested in the corresponding strains
deficient in one or two nitroreductases. A summary of the
results is shown in Table I. Figures 4–7 show the results for
TA98 and TA100 plus their nitroreductase-deficient counter-
parts, with (Figures 4 and 5) and without (Figures 6 and 7–9)
metabolic activation (S9). Mutagenicity was observed in all
strains to different degrees, except in TA1537 where the
original weak positive response was not reproducible. In each



































Fig. 3. Metabolism of fexinidazole in vitro following incubation with rat liver
S9 (HPLC data). Regions 1 and 2 represent the positions of fexinidazole
sulfone and fexinidazole sulfoxide, respectively.
Fig. 2. Nitroreductase activities of various strains used in this study, including
TA1537NR (YG7167) and TA102NR (YG7168).
Table I. Summary of Ames test data on fexinidazole showing the lowest
detectable mutagenic response (micrograms per plate)a
Ames strainb �S9 þS9
TA1535 20 4
TA1535NR Negative 350
TA1535 delta NR (YG7127) 350 4–20
TA1537 Negative 100 (negative
in a repeat study)






TA102NR (YG7168) Negative 158
aBased on a .2-fold increase in concurrent negative control values.
bStrains possessing active major nitroreductase (NR) genes—TA100, TA1537
and TA102 ; strains lacking an active classical NR gene—TA100NR; YG7127
(TA1535 derivative), YG7167 (TA1537 derivative) and YG7168 (TA102
derivative); strain lacking an active supplementary NR gene (TA98) and strains
lacking both major NR genes—TA98NR and TA1535NR.
Fig. 4. Ames tests of fexinidazole using strains TA98 and TA98NR (absence
of S9).
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or significantly attenuated (e.g. TA100NR versus TA100) in
the strains deficient in nitroreductase compared to their
nitoreductase-proficient counterpart. In the strains lacking both
the classical nitroreductase and the supplementary nitro-
reductase, i.e.TA98NR and TA1535NR, mutagenicity was all
but abolished, suggesting that the residual mutagenicity seen in
the other strains was due to the activity of the supplementary
nitroreductase. These data suggest that the positive mutage-
nicity signal observed for fexinidazole in the Ames test is due
to a reduction of fexinidazole by either or both bacterial
nitroreductases.
In most cases where mutagenicity was observed, potency of
the signal was increased in the presence of rat liver S9. As
fexinidazole is rapidly metabolised to its sulfoxide by rat liver
S9 (Figure 2), this suggests that this metabolite is a more active
bacterial mutagen than fexinidazole itself. In the absence of rat
liver S9, no activity was observed in TA102. However, activity
was observed in this strain in the presence of S9. These data
suggest that the sulfoxide possesses additional mutagenic
activity for this strain. However, again, activity was attenuated
in the nitroreductase-deficient derivative showing that nitro-
reduction plays a part in the mutagenicity observed.
Ames tests of fexinidazole sulfone
As only trace amounts of fexinidazole sulfone are formed by
incubation of fexinidazole with rat liver S9, this metabolite was
tested in its own right. As this compound is a metabolite, tests
were carried out in the absence of rat liver S9 only. The results
shown in Table II and Figures 8 and 9 for TA98 and TA100 (plus
their nitroreductase-deficient counterparts) demonstrate a broadly
similar result to fexinidazole, with mutagenic activity lost or
attenuated in the strains deficient in nitroreductase activity.
In vitro micronucleus tests of fexinidazole and fexinidazole
sulfone
Both fexinidazole and fexinidazole sulfone were subsequently
tested in in vitro micronucleus tests using human peripheral
lymphocytes. As it was shown that fexinidazole is metabolised
to its sulfoxide under the conditions of the assay, the results
shown in Table IIIa and b cover fexinidazole and fexinidazole
sulfoxide. The results for fexinidazole sulfone are shown in
Table IV. Neither compound induces chromosome damage in
human lymphocytes under the conditions of these assays. Thus,
the mutagenic potential seen in the bacterial Ames test is not
realised in these mammalian cells in vitro.
Fig. 6. Ames tests of fexinidazole using strains TA100 and TA100NR
(absence of S9).
Fig. 5. Ames tests of fexinidazole using strains TA98 and TA98NR (presence
of S9).
Fig. 7. Ames tests of fexinidazole using strains TA100 and TA100NR
(presence of S9).
Table II. Summary of Ames test data on fexinidazole sulfone showing the












aBased on a .2-fold increase in concurrent negative control values.
bStrains possessing active major nitroreductase (NR) genes—TA100, TA1537
and TA102; strains lacking an active classical NR gene—TA100NR; YG7167
(TA1537 derivative) and YG7168 (TA102 derivative); strain lacking an active
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In vivo mouse bone marrow micronucleus test
Fexinidazole was subsequently tested in an in vivo bone
marrow micronucleus test. As shown in Table V, even when
given at doses up to the maximum recognised by international
guidelines, fexinidazole does not induce chromosomal damage
in this assay, confirming the lack of activity seen in the in vitro
micronucleus study. A preliminary study had also been carried
out at the CIT Laboratories in France with the same outcome
(data not shown). The exposure to fexinidazole and the
sulfoxide and sulfone metabolites in these assays was
confirmed by HPLC analysis (Table VIIa).
Ex vivo UDS test
The rationale for choosing the ex vivo UDS test as the second
in vivo test was as follows:
1. Previous studies carried out by Bayer had shown that UDS
was detected at low doses in three of five tests of
fexinidazole using A549 cells in vitro. Thus, there was
a wish to explore this endpoint in an in vivo test.
2. Fexinidazole is relatively non-toxic in rat studies given high
doses for 28 days (32). The only target organ in the rat is the
liver where increased liver weight and hypertrophy of
centrilobular hepatocytes were seen.
3. The liver is the site of primary metabolism of fexinidazole,
so the cells in this organ are exposed to the highest
concentrations of the major metabolites. It is also likely that
the liver is also exposed to high concentrations of the parent
fexinidazole as it is rapidly metabolised by the liver,
reducing systemic exposure, as per the toxicokinetic profile
in this paper and from separate drug metabolism pharma-
cokinetic studies (32).
4. Some nitro goup containing aromatic compounds have been
shown to induce UDS in hepatocytes in vitro and in vivo
(41,42).
As shown in Table VI, there was no indication of any UDS
at any dose at either time point. The exposure to fexinidazole
and the sulfoxide and sulfone metabolites in this study was
confirmed by HPLC analysis (Table VIIb).
Redox potential studies
It is known that the nitroreductase enzymes in bacteria can
nitroreduce compounds at low redox potentials, whereas
equivalent mammalian enzymes cannot, under normal con-
ditions. Fexinidazole, the sulfoxide and the sulfone were
shown to have low single-electron redox potentials being
511, 493 and 488 mV, respectively. The same parameter
for metronidazole was 516 mV and megazol was signifi-
cantly less negative at 422 mV.
Discussion
Substituted nitroimidazoles are widely used as antimicrobials
and anti-parasitic compounds, but there are persistent concerns
about genetic toxicity and potential carcinogenicity of the drugs
in present use. There is a pressing need for an effective, safe and
easy to administer therapy for African sleeping sickness (HAT).
Fexinidazole, a 5-nitroimidazole dropped from drug develop-
ment by Hoechst in the 1980’s, was rediscovered by DNDi as
a potential new treatment for HAT. The potent anti-trypanosomal
activity of fexinidazole was confirmed in acute mouse models,
including being able to cure a stringent model of second stage
HAT and the chronic mouse model involving brain infection
(32). As part of the efforts to develop this compound for possible
therapeutic use, a full toxicology battery was completed,
including a full assessment of genotoxicity.
Because fexinidazole is rapidly metabolised in vivo to
sulfoxide and sulfone metabolites, the studies were designed to
include the assessment of both metabolites. Metabolism studies
in vitro showed that the sulfoxide metabolite is formed efficiently
by rat liver S9 in the conditions of the in vitro genotoxicity
assays, but only traces of the sulfone metabolite were detected.
Therefore, the in vitro genotoxicity studies (Ames and in vitro
micronucleus test) were repeated with this compound. For the in
vivo studies, the adequate exposure to all three compounds was
confirmed by measuring the plasma levels in satellite animals.
As expected, mutagenic activity was observed for fexinida-
zole and its metabolites in the Ames test. However, this activity
was attenuated or lost in Ames strains lacking one or more of
the nitroreductases normally present in the Salmonella cells. It
is known that bacterial nitroreductases can reduce nitro-
containing compounds of low redox potentials, whereas the
mammalian counterparts cannot. This nitroreduction results in
the formation of reactive chemical species with potential to
Fig. 9. Ames tests of sulfone metabolite using strains TA100 and TA100NR
(absence of S9).




react with DNA and thus cause genetic damage. The
observation that the mutagenic activity is attenuated or lost in
Salmonella strains deficient in nitroreductases suggests that
mutagenicity is not an intrinsic property of these compounds
but the result of activation by bacteria-specific nitroreductases.
When tested in the in vitro micronucleus test on human
lymphocytes, the in vivo bone marrow micronucleus test and
the ex vivo UDS test rat liver cells, no mutagenic activity was
seen for fexinidazole and its sulfoxide and sulfone metabolites.
Toxicokinetic studies demonstrated significant exposure to all
the three compounds in the plasma of the treated animals and
thus, the bone marrow and the liver were used as targets for
genotoxicity evaluations. This combination of tests meets the
ICH (S2B) genotoxicity testing requirements for registration of
new pharmaceuticals.
Redox measurements showed that fexinidazole and its
sulfoxide and sulfone metabolites possess highly negative
single-electron redox potentials of �511, �493 and �488 mV,
respectively. This is consistent with the absence of mutagenic
activity in mammalian cells as mammalian nitroreductases are
expected to be incapable of nitro-reducing compounds with
such negative single-electron redox potentials.
The potential of nitrogroup containing compounds to cause
mutagenic damage to intestinal cells following nitroreduction
by bacteria in the intestinal flora, with possible diffusion of
reduced metabolites has been contested in the literature
for more than 30 years (review 43). However, this is deemed
unlikely to be significant due to the short half-life of reduced
intermediates of 5-nitroimidazoles and the failure to detect
nitroreduced metabolites of compounds like metronidazole in
the intestine of human patients (44). This issue was considered
by the Scientific Committee for Animal Nutrition (SCAN) of
the European Commission for the 5-nitroimidazole dimetrini-
dazole (metronidazole was also discussed). Dimetrinidazole










3 þ 24 h Vehiclea — — 0.70 —
Sulfone 300 0 0.45 NS
Sulfone 400 7 0.40 NS
Sulfone 500b 14 0.35 NS
MMCc 0.8 ND 11.90 P , 0.001
24 h þ 0 Vehiclea — — 0.15 NS
Sulfone 50 21 0.25 NS
Sulfone 100 25 0.35 NS
Sulfone 200b 59 0.15 NS
VINc 0.02 ND 17.01 P , 0.001
NS, not significant; ND, not determined.
aThe vehicle was DMSO.
bThe highest concentrations selected were selected on toxicity, precipitation or a maximum of 500 lg/ml.
cThe positive controls were mitomycin C (MMC) and vinblastine (VIN).
Table III. In vitro micronucleus tests of fexinidazole using human peripheral lymphocytes
Treatment Compound Concentration (lg/ml) Cytotoxicity (%) Mean MNBN cell frequency Statistical significance
24-h PHA
20 þ 28 h (–S9) Vehiclea — — 0.75 —
Fexinidazole 20.0 19 0.50 NS
Fexinidazole 40.0 0 0.40 NS
Fexinidazole 80.0b 32 0.70 NS
5NQOc 5.0 ND 10.80 P , 0.001
3 þ 45 h (þS9) Vehiclea — — 0.40 —
Fexinidazole 80.0 27 0.50 NS
Fexinidazole 140.0 43 0.55 NS
Fexinidazole 180.0b 47 0.75 NS
CPAc 6.25 ND 3.60 P , 0.001
48-h PHA
20 þ 28h (�S9) Vehiclea — — 1.05 —
Fexinidazole 20.0 4 1.10 NS
Fexinidazole 40.0 23 0.60 NS
Fexinidazole 80.0b 29 0.85 NS
5NQOc 5.0 ND 8.95 P , 0.001
3 þ 45 h (þS9) Vehiclea — — 0.90 —
Fexinidazole 80.0 2 0.60 NS
Fexinidazole 140.0 13 1.20 NS
Fexinidazole 180.0b 8 0.35 NS
CPAc 6.25 ND 12.85 P , 0.001
NS, not significant; ND, not determined.
aThe vehicle was DMSO.
bThe highest concentrations selected were the maximum practicable concentrations limited by precipitation observed at the end of the treatment period.
cThe positive controls were 5-nitroquinoline-N-oxide (5NQO) –S9 and cyclophosphamide (CPA) þS9.
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In vivo mouse bone marrow micronucleus test
Fexinidazole was subsequently tested in an in vivo bone
marrow micronucleus test. As shown in Table V, even when
given at doses up to the maximum recognised by international
guidelines, fexinidazole does not induce chromosomal damage
in this assay, confirming the lack of activity seen in the in vitro
micronucleus study. A preliminary study had also been carried
out at the CIT Laboratories in France with the same outcome
(data not shown). The exposure to fexinidazole and the
sulfoxide and sulfone metabolites in these assays was
confirmed by HPLC analysis (Table VIIa).
Ex vivo UDS test
The rationale for choosing the ex vivo UDS test as the second
in vivo test was as follows:
1. Previous studies carried out by Bayer had shown that UDS
was detected at low doses in three of five tests of
fexinidazole using A549 cells in vitro. Thus, there was
a wish to explore this endpoint in an in vivo test.
2. Fexinidazole is relatively non-toxic in rat studies given high
doses for 28 days (32). The only target organ in the rat is the
liver where increased liver weight and hypertrophy of
centrilobular hepatocytes were seen.
3. The liver is the site of primary metabolism of fexinidazole,
so the cells in this organ are exposed to the highest
concentrations of the major metabolites. It is also likely that
the liver is also exposed to high concentrations of the parent
fexinidazole as it is rapidly metabolised by the liver,
reducing systemic exposure, as per the toxicokinetic profile
in this paper and from separate drug metabolism pharma-
cokinetic studies (32).
4. Some nitro goup containing aromatic compounds have been
shown to induce UDS in hepatocytes in vitro and in vivo
(41,42).
As shown in Table VI, there was no indication of any UDS
at any dose at either time point. The exposure to fexinidazole
and the sulfoxide and sulfone metabolites in this study was
confirmed by HPLC analysis (Table VIIb).
Redox potential studies
It is known that the nitroreductase enzymes in bacteria can
nitroreduce compounds at low redox potentials, whereas
equivalent mammalian enzymes cannot, under normal con-
ditions. Fexinidazole, the sulfoxide and the sulfone were
shown to have low single-electron redox potentials being
511, 493 and 488 mV, respectively. The same parameter
for metronidazole was 516 mV and megazol was signifi-
cantly less negative at 422 mV.
Discussion
Substituted nitroimidazoles are widely used as antimicrobials
and anti-parasitic compounds, but there are persistent concerns
about genetic toxicity and potential carcinogenicity of the drugs
in present use. There is a pressing need for an effective, safe and
easy to administer therapy for African sleeping sickness (HAT).
Fexinidazole, a 5-nitroimidazole dropped from drug develop-
ment by Hoechst in the 1980’s, was rediscovered by DNDi as
a potential new treatment for HAT. The potent anti-trypanosomal
activity of fexinidazole was confirmed in acute mouse models,
including being able to cure a stringent model of second stage
HAT and the chronic mouse model involving brain infection
(32). As part of the efforts to develop this compound for possible
therapeutic use, a full toxicology battery was completed,
including a full assessment of genotoxicity.
Because fexinidazole is rapidly metabolised in vivo to
sulfoxide and sulfone metabolites, the studies were designed to
include the assessment of both metabolites. Metabolism studies
in vitro showed that the sulfoxide metabolite is formed efficiently
by rat liver S9 in the conditions of the in vitro genotoxicity
assays, but only traces of the sulfone metabolite were detected.
Therefore, the in vitro genotoxicity studies (Ames and in vitro
micronucleus test) were repeated with this compound. For the in
vivo studies, the adequate exposure to all three compounds was
confirmed by measuring the plasma levels in satellite animals.
As expected, mutagenic activity was observed for fexinida-
zole and its metabolites in the Ames test. However, this activity
was attenuated or lost in Ames strains lacking one or more of
the nitroreductases normally present in the Salmonella cells. It
is known that bacterial nitroreductases can reduce nitro-
containing compounds of low redox potentials, whereas the
mammalian counterparts cannot. This nitroreduction results in
the formation of reactive chemical species with potential to
Fig. 9. Ames tests of sulfone metabolite using strains TA100 and TA100NR
(absence of S9).
Fig. 8. Ames tests of sulfone metabolite using strains TA98 and TA98NR
(absence of S9).
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react with DNA and thus cause genetic damage. The
observation that the mutagenic activity is attenuated or lost in
Salmonella strains deficient in nitroreductases suggests that
mutagenicity is not an intrinsic property of these compounds
but the result of activation by bacteria-specific nitroreductases.
When tested in the in vitro micronucleus test on human
lymphocytes, the in vivo bone marrow micronucleus test and
the ex vivo UDS test rat liver cells, no mutagenic activity was
seen for fexinidazole and its sulfoxide and sulfone metabolites.
Toxicokinetic studies demonstrated significant exposure to all
the three compounds in the plasma of the treated animals and
thus, the bone marrow and the liver were used as targets for
genotoxicity evaluations. This combination of tests meets the
ICH (S2B) genotoxicity testing requirements for registration of
new pharmaceuticals.
Redox measurements showed that fexinidazole and its
sulfoxide and sulfone metabolites possess highly negative
single-electron redox potentials of �511, �493 and �488 mV,
respectively. This is consistent with the absence of mutagenic
activity in mammalian cells as mammalian nitroreductases are
expected to be incapable of nitro-reducing compounds with
such negative single-electron redox potentials.
The potential of nitrogroup containing compounds to cause
mutagenic damage to intestinal cells following nitroreduction
by bacteria in the intestinal flora, with possible diffusion of
reduced metabolites has been contested in the literature
for more than 30 years (review 43). However, this is deemed
unlikely to be significant due to the short half-life of reduced
intermediates of 5-nitroimidazoles and the failure to detect
nitroreduced metabolites of compounds like metronidazole in
the intestine of human patients (44). This issue was considered
by the Scientific Committee for Animal Nutrition (SCAN) of
the European Commission for the 5-nitroimidazole dimetrini-
dazole (metronidazole was also discussed). Dimetrinidazole










3 þ 24 h Vehiclea — — 0.70 —
Sulfone 300 0 0.45 NS
Sulfone 400 7 0.40 NS
Sulfone 500b 14 0.35 NS
MMCc 0.8 ND 11.90 P , 0.001
24 h þ 0 Vehiclea — — 0.15 NS
Sulfone 50 21 0.25 NS
Sulfone 100 25 0.35 NS
Sulfone 200b 59 0.15 NS
VINc 0.02 ND 17.01 P , 0.001
NS, not significant; ND, not determined.
aThe vehicle was DMSO.
bThe highest concentrations selected were selected on toxicity, precipitation or a maximum of 500 lg/ml.
cThe positive controls were mitomycin C (MMC) and vinblastine (VIN).
Table III. In vitro micronucleus tests of fexinidazole using human peripheral lymphocytes
Treatment Compound Concentration (lg/ml) Cytotoxicity (%) Mean MNBN cell frequency Statistical significance
24-h PHA
20 þ 28 h (–S9) Vehiclea — — 0.75 —
Fexinidazole 20.0 19 0.50 NS
Fexinidazole 40.0 0 0.40 NS
Fexinidazole 80.0b 32 0.70 NS
5NQOc 5.0 ND 10.80 P , 0.001
3 þ 45 h (þS9) Vehiclea — — 0.40 —
Fexinidazole 80.0 27 0.50 NS
Fexinidazole 140.0 43 0.55 NS
Fexinidazole 180.0b 47 0.75 NS
CPAc 6.25 ND 3.60 P , 0.001
48-h PHA
20 þ 28h (�S9) Vehiclea — — 1.05 —
Fexinidazole 20.0 4 1.10 NS
Fexinidazole 40.0 23 0.60 NS
Fexinidazole 80.0b 29 0.85 NS
5NQOc 5.0 ND 8.95 P , 0.001
3 þ 45 h (þS9) Vehiclea — — 0.90 —
Fexinidazole 80.0 2 0.60 NS
Fexinidazole 140.0 13 1.20 NS
Fexinidazole 180.0b 8 0.35 NS
CPAc 6.25 ND 12.85 P , 0.001
NS, not significant; ND, not determined.
aThe vehicle was DMSO.
bThe highest concentrations selected were the maximum practicable concentrations limited by precipitation observed at the end of the treatment period.
cThe positive controls were 5-nitroquinoline-N-oxide (5NQO) –S9 and cyclophosphamide (CPA) þS9.
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has a similar genotoxicity profile to fexinidazole. The SCAN
committee noted that ‘when the production within intestinal
flora of DMZ reactive metabolites is concerned, it must be noted
that the lifetime of these metabolites depends on the reduction
potential of the parent molecule the lower the potential the
longer is the half-life (12 sec for 5-nitroimidazoles) and the
more limited is the damage (45). The absence in long-term
studies with 5-nitroimidazole compounds of intestinal tumours
is consistent with these observations (46). In support of this,
latter statement for the related nitro-containing compounds (all
of whom induce mutations in the Ames test due to bacterial
nitroreduction), metronidazole (47,48), benznidazole (49) and
nifurtimox (50) have all been tested for carcinogenicity in
rodents and none have produced intestinal tumours. In further
support of the lack of proven hazard to intestinal cells for nitro-
containing compounds, a study of AMP397, a compound with
this chemical substructure (see Figure 10) proposed for use as
an anti-epilectic, addressed the issue of possible gut bacteria
generated genotoxins due to nitroreduction (51). AMP397 has
a very similar profile to fexinidazole in genotoxicity tests:
mutagenic activity was observed in the standard Ames test
strains but loss of that activity in their nitroreductase-deficient
counterparts and negative results in the chosen mammalian cell
assays. A mutagenicity study was carried out in vivo in the
MutaMouse model, in which the test animals were given five
daily treatments of AMP397 at the maximum tolerated dose.
Samples were taken at 3, 7 and 31 days after treatment. No
evidence of mutagenicity was seen in the colon or liver.
Similarly, an in vivo comet assay in the rat (measuring DNA
strand breakage) did not detect any genetic damage in the
jejunum or liver of treated animals after dosing the animals at
a dose six times higher than that possible in the MutaMouse
study. A radioactive DNA-binding study of AMP397 also
failed to show any DNA binding in rat liver. Thus, if
a mutagenic metabolite was formed by intestinal bacteria, it
was unable to induce genetic damage in local intestinal tissue.
In summary, there is no evidence to prove that 5-
nitroimidazoles (and compounds with related nitro-containing
substructures) pose a genotoxic or carcinogenic risk to intestinal
cells, whereas there is significant evidence that supports a lack of
risk from this theoretical pathway. It is legitimate to consider 5-
nitroimidazoles as a class with similar biological properties; thus,
there is no compelling reason to regard fexinidazole as separate
to the examples given above. However, to provide additional
weight of evidence as to its lack of genotoxicity, an additional in
vivo assay measuring effects on cells of the GI tract (e.g. a Comet
assay) would be of value.
Taken together, these studies show that fexinidazole is
unlikely to pose a genotoxic hazard for patients. In terms of
human hazard assessment, it is important to recognise that any
treatment of patients with fexinidazole will be short-term (7–14
days), multiple treatments are unlikely, HAT is 100% lethal if
untreated, most existing treatments are either highly toxic and
are becoming increasingly ineffective due to resistance of the
parasite. Fexinidazole has received regulatory approval for the
conduct of studies in humans from the French regulatory
authorities (AFSSAPS) and is undergoing clinical trials (http://
clinicaltrials.gov/ct2/show/NCT00982904). There are further
nitroimidazoles under investigation for possible development
Table V. Bone marrow micronucleus test of fexinidazole in Crl:CD-1 (ICR)
mice





CPAb^ 40 19.7 46.95
aThe vehicle was Methocel 0.5% (w/v) with 5% (v/v) Tween 80.
bThe positive control was cyclophosphamide (CPA).
Table VI. Ex vivo UDS test of fexinidazole in rat hepatocytes






Vehiclea — 0.2 0.6
Fexinidazole 500 0.0 0.4
Fexinidazole 1000 0.1 0.6
Fexinidazole 2000 0.4 0.2
DMNb 10 8.9 —
2-AAFb 75 — 9.8
aThe vehicle was Methocel 0.5% (w/v) with 5% (v/v) Tween 80.
bPositive controls were dimethylnitrosamine (DMN) and 2-acetamidofluorene
(2-AAF).
Table VII. Plasma levels of fexinidazole, fexinidazole sulfoxide and fexnidazole sulfone in satellite animals from the (a) in vivo bone marrow micronucleus studies
in the mouse and (b) from the ex-vivo UDS study in rat














Acceleraa Mouse 2000 1.0 1080.0 30 666.7 57 333.3
CITb Mouse 2000 4.0 300.7 20 766.7 107 233.3
(b)
Acceleraa Rat 2000 1.0 988.0 27 667.0 5017.0
aNerviano Medical Science, S.r.l., Accelera, Milan, Italy.
bCIT, Evreux, France.
Fig. 10. Chemical structure of AMP397.
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for use in treating HAT and Chagas disease that are being
selected on the basis of high efficacy and low genotoxic
potential (52).
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has a similar genotoxicity profile to fexinidazole. The SCAN
committee noted that ‘when the production within intestinal
flora of DMZ reactive metabolites is concerned, it must be noted
that the lifetime of these metabolites depends on the reduction
potential of the parent molecule the lower the potential the
longer is the half-life (12 sec for 5-nitroimidazoles) and the
more limited is the damage (45). The absence in long-term
studies with 5-nitroimidazole compounds of intestinal tumours
is consistent with these observations (46). In support of this,
latter statement for the related nitro-containing compounds (all
of whom induce mutations in the Ames test due to bacterial
nitroreduction), metronidazole (47,48), benznidazole (49) and
nifurtimox (50) have all been tested for carcinogenicity in
rodents and none have produced intestinal tumours. In further
support of the lack of proven hazard to intestinal cells for nitro-
containing compounds, a study of AMP397, a compound with
this chemical substructure (see Figure 10) proposed for use as
an anti-epilectic, addressed the issue of possible gut bacteria
generated genotoxins due to nitroreduction (51). AMP397 has
a very similar profile to fexinidazole in genotoxicity tests:
mutagenic activity was observed in the standard Ames test
strains but loss of that activity in their nitroreductase-deficient
counterparts and negative results in the chosen mammalian cell
assays. A mutagenicity study was carried out in vivo in the
MutaMouse model, in which the test animals were given five
daily treatments of AMP397 at the maximum tolerated dose.
Samples were taken at 3, 7 and 31 days after treatment. No
evidence of mutagenicity was seen in the colon or liver.
Similarly, an in vivo comet assay in the rat (measuring DNA
strand breakage) did not detect any genetic damage in the
jejunum or liver of treated animals after dosing the animals at
a dose six times higher than that possible in the MutaMouse
study. A radioactive DNA-binding study of AMP397 also
failed to show any DNA binding in rat liver. Thus, if
a mutagenic metabolite was formed by intestinal bacteria, it
was unable to induce genetic damage in local intestinal tissue.
In summary, there is no evidence to prove that 5-
nitroimidazoles (and compounds with related nitro-containing
substructures) pose a genotoxic or carcinogenic risk to intestinal
cells, whereas there is significant evidence that supports a lack of
risk from this theoretical pathway. It is legitimate to consider 5-
nitroimidazoles as a class with similar biological properties; thus,
there is no compelling reason to regard fexinidazole as separate
to the examples given above. However, to provide additional
weight of evidence as to its lack of genotoxicity, an additional in
vivo assay measuring effects on cells of the GI tract (e.g. a Comet
assay) would be of value.
Taken together, these studies show that fexinidazole is
unlikely to pose a genotoxic hazard for patients. In terms of
human hazard assessment, it is important to recognise that any
treatment of patients with fexinidazole will be short-term (7–14
days), multiple treatments are unlikely, HAT is 100% lethal if
untreated, most existing treatments are either highly toxic and
are becoming increasingly ineffective due to resistance of the
parasite. Fexinidazole has received regulatory approval for the
conduct of studies in humans from the French regulatory
authorities (AFSSAPS) and is undergoing clinical trials (http://
clinicaltrials.gov/ct2/show/NCT00982904). There are further
nitroimidazoles under investigation for possible development
Table V. Bone marrow micronucleus test of fexinidazole in Crl:CD-1 (ICR)
mice





CPAb^ 40 19.7 46.95
aThe vehicle was Methocel 0.5% (w/v) with 5% (v/v) Tween 80.
bThe positive control was cyclophosphamide (CPA).
Table VI. Ex vivo UDS test of fexinidazole in rat hepatocytes






Vehiclea — 0.2 0.6
Fexinidazole 500 0.0 0.4
Fexinidazole 1000 0.1 0.6
Fexinidazole 2000 0.4 0.2
DMNb 10 8.9 —
2-AAFb 75 — 9.8
aThe vehicle was Methocel 0.5% (w/v) with 5% (v/v) Tween 80.
bPositive controls were dimethylnitrosamine (DMN) and 2-acetamidofluorene
(2-AAF).
Table VII. Plasma levels of fexinidazole, fexinidazole sulfoxide and fexnidazole sulfone in satellite animals from the (a) in vivo bone marrow micronucleus studies
in the mouse and (b) from the ex-vivo UDS study in rat














Acceleraa Mouse 2000 1.0 1080.0 30 666.7 57 333.3
CITb Mouse 2000 4.0 300.7 20 766.7 107 233.3
(b)
Acceleraa Rat 2000 1.0 988.0 27 667.0 5017.0
aNerviano Medical Science, S.r.l., Accelera, Milan, Italy.
bCIT, Evreux, France.
Fig. 10. Chemical structure of AMP397.
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for use in treating HAT and Chagas disease that are being
selected on the basis of high efficacy and low genotoxic
potential (52).
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